Aria CV is a developer of medical devices designed to improve the lives of patients living with the disease of Pulmonary Arterial Hypertension (PAH).
Aria CV is improving the lives of patients suffering from the disease of pulmonary hypertension.
Aria CV was founded in 2010 by John Scandurra and Karl Vollmers. The company is headquartered in ST. Paul, Minnesota.
ARia CV's PAH is a progressive and highly debilitating disease that often leads to heart failure. The implanted Aria CV PH System is designed to restore the benefits of a healthy, elastic pulmonary artery, which in turn reduces cardiac workload and enhances blood flow.
Aria has performed a successful acute first in human clinical study in Vienna, Austria and is now preparing for a U.S. clinical trial under the FDA’s Early Feasibility Study Program to evaluate long term implants in PAH patients.
Aria CV is backed by Xeraya Capital, Longview Ventures, Catalyst Health Ventures, BioStar Ventures, Cedar Point Capital, Frontcourt Group and others. The company raised $31M in a Series B round on Feb 25, 2020. This brings Aria CV's total funding to $40.7M to date.